Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 19, Issue 4, 2012, Pages 413-425

  Murata, Yasuhiro ^a   Hamada, Takashi ^a   Kishiwada, Masashi ^a   Ohsawa, Ichiro ^a   Mizuno, Shugo ^a   Usui, Masanobu ^a   Sakurai, Hiroyuki ^a   Tabata, Masami ^a   Ii, Noriko ^a   Inoue, Hiroyuki ^a   Shiraishi, Taizo ^a   Isaji, Shuji ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiotherapy (CRT); Gemcitabine; Human equilibrative nucleoside transporter 1 (hENT1); Pancreatic cancer; Survival analysis

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CHEMORADIOTHERAPY, ADJUVANT; DIHYDROURACIL DEHYDROGENASE (NADP); EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NUTRITION ASSESSMENT; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 84867404707     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-011-0440-3     Document Type: Article

References (39)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-13.
2. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019-26.
3. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3): 267-77.
4. Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, et al. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 2008; 26 (Suppl 15) (abstract 4504).
5. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27(3):324-9.
6. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006;10(10):1338-45. (discussion 1345-6).
7. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758-68.
8. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035-46.
9. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496-502.
10. Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent threedimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250(1):88-95.
11. Talamonti MS, Small W Jr, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13(2):150-8.
12. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 20, 20-difluoro- 20-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34(4): 867-72.
13. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor- Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 20,20-difluorodeoxycytidineinduced cytotoxicity. Clin Cancer Res. 2003;9:5000-8.
14. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58(19):4349-57.
15. Mori R, Ishikawa T, Ichikawa Y, Taniguchi K, Matsuyama R, Ueda M, et al. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep. 2007;17:1201-5.
16. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136(1):187-95.
17. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009;15(8):2913-9.
18. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, et al. Impact of S-1 on the survival of patients with advanced pancreatic cancer. Pancreas. 2010;39(7):989-93.
19. Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, et al. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res. 2003;9(11):4165-71.
20. Nakayama S, Takeda S, Kawase Y, Inoue S, Kaneko T, Nakao A. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg. 2004;240(5):840-4.
21. Komori S, Osada S, Mori R, Matsui S, Sanada Y, Tomita H, et al. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer. Pancreas. 2010;39(8): 1284-92.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
23. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11): 1335-9.
24. Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 2007; 256(1):112-9.
25. Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, et al. Immunohistochemical variation of human nucleoside transporters in primary breast cancers. Clin Cancer Res. 2002;8:110-6.
26. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, et al. Immunohistochemical demonstration of fluoropyrimidine- metabolizing enzymes in various types of cancer. Oncol Rep. 2005;14(5):1223-30.
27. Hosokawa A, Yamada Y, Shimada Y, Muro K, Hamaguchi T, Morita H, et al. Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. Int J Clin Oncol. 2004; 9(5):388-92.
28. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10(20):6956-61.
29. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996;78(3 Suppl):627-32.
30. Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg. 1996;172(4):350-2.
31. Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32(1):35-41.
32. Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20(5):1182-91.
33. Gregoire V, Hittelman WN, Rosier JF, Milas L. Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Oncol Rep. 1999;6(5):949-57.
34. Fischel JL, Etienne MC, Spector T, Formento P, Renée N, Milano G. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin Cancer Res. 1995;1(9):991-6.
35. Kamoshida S, Matsuoka H, Ishikawa T, Maeda K, Shimomura R, Inada K, et al. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. Jpn J Clin Oncol. 2004;34(10):594-601.
36. Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracilbased adjuvant chemotherapy. Langenbecks Arch Surg. 2010; 395(3):217-25.
37. Formentini A, Sander S, Denzer S, Straeter J, Henne-Bruns D, Kornmann M. Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? Int J Colorectal Dis. 2007;22(1):49-55.
38. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66(7):3928-35.
39. Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, et al. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol. 2007;42(5):389-94.